GWP
AKBA icon

Gen-Wealth Partners’s Akebia Therapeutics AKBA Stock Holding History

Gen-Wealth Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62K Hold
2,295
– – ﹤0.01% 629
2026
Q1 		$3.19K Hold
2,295
– – ﹤0.01% 619
2025
Q4 		$3.69K Hold
2,295
– – ﹤0.01% 581
2025
Q3 		$6.26K Buy
+2,295
New +$7.63K ﹤0.01% 552

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Gen-Wealth Partners's AKBA Position: Q2 2026 in Review

Gen-Wealth Partners held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 2,295 shares worth $2.62K. The position accounts for ﹤0.01% of the portfolio, ranked #629.

Gen-Wealth Partners first reported a position in AKBA in Q3 2025 and has held it in 4 quarters since. The position peaked at $6.26K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Gen-Wealth Partners held 2,295 shares of Akebia Therapeutics worth $2.62K as of Q2 2026.
  • Gen-Wealth Partners left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #629 holding.
  • Gen-Wealth Partners first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Gen-Wealth Partners's Akebia Therapeutics position peaked at $6.26K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.